IMR Press / EJGO / Volume 20 / Issue 1 / pii/1999105

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Case Report

The combination paclitaxel, carboplatin and megestrol acetate is effective in women with recurrent uterine papillary serous adenocarcinoma

Show Less
1 Division of Gynecologic Oncology, University of Vermont, Burlington, Vermont, USA
Eur. J. Gynaecol. Oncol. 1999, 20(1), 18–19;
Published: 10 February 1999

Uterine papillary serous adenocarcinoma is an uncommon and very aggressive type of endometrial cancer. A 76-year-old patient diagnosed with recurrent uterine papillary serous adenocarcinoma was prescribed megesterol acetate (160 mg daily), paclitaxel (135 mg/m2) and carboplatin (area under the concentration-time curve of 5) every 4 weeks for 4 courses. She demonstrated complete cli­nical response that was maintained for longer than 6 months with minimal toxicity. The combination megesterol acetate, paclitaxel and carboplatin may be effective in women with recurrent uterine papillary serous adenocarcinoma.

Recurrent endometrial cancer
Uterine papillary serous adenocarcinoma
Mege-sterol acetate
Back to top